Evidence map›Paper›PMID 36577072›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

The lncRNA LUCAT1 is elevated in inflammatory disease and restrains inflammation by regulating the splicing and stability of NR4A2.

Tim Vierbuchen, Shiuli Agarwal, John L Johnson, Liraz Galia, Xuqiu Lei, Karina Stein, David Olagnier, Karoline I Gaede, Christian Herzmann, Christian K Holm and 5 more

Open access · goldAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Genomic crosstalk between carbachol, a muscarinic receptor agonist, and the long-acting βThe Journal of pharmacology and experimental therapeutics · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Non-coding RNA Networks in Infection.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Tim VierbuchenDivision of Innate Immunity, University of Massachusetts Chan Medical School, Worcester, MA 01605.
Shiuli AgarwalDivision of Innate Immunity, University of Massachusetts Chan Medical School, Worcester, MA 01605.
John L JohnsonJanssen R&D, Discovery, Spring House, PA 19002.
Liraz GaliaDivision of Innate Immunity, University of Massachusetts Chan Medical School, Worcester, MA 01605.ORCID 0000-0002-7502-8062
Xuqiu LeiDivision of Innate Immunity, University of Massachusetts Chan Medical School, Worcester, MA 01605.ORCID 0000-0003-3565-6969
Karina SteinDivision of Innate Immunity, Research Center Borstel-Leibniz Lung Center, Borstel 23845, Germany.
David OlagnierDepartment of Biomedicine, Aarhus University, Aarhus 8000, Denmark.
Karoline I GaedeGerman Center for Lung Research, Airway Research Center North, Borstel 23845, Germany.
Christian HerzmannCenter for Clinical Studies, Research Center Borstel-Leibniz Lung Center, Borstel 23845, Germany.
Christian K HolmDepartment of Biomedicine, Aarhus University, Aarhus 8000, Denmark.
Holger HeineDivision of Innate Immunity, Research Center Borstel-Leibniz Lung Center, Borstel 23845, Germany.ORCID 0000-0001-8128-5068
Athma PaiRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605.
Aisling O'Hara HallBristol Myers Squibb, Immunology Cardiovascular and Fibrosis Translational Early Development, Summit, NJ 07901.
Kasper HoebeJanssen R&D, Discovery, Spring House, PA 19002.
Katherine A FitzgeraldDivision of Innate Immunity, University of Massachusetts Chan Medical School, Worcester, MA 01605.
Hinge Health · USUniversity of Massachusetts Chan Medical School · USAarhus University · DKBristol-Myers Squibb (United States) · US

Funding

Gene Regulation in Innate ImmunityR37AI067497 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, KATHERINE A. · 2015 to 2024
$4.6M
Regulation of Type I Interferon Gene Expression in the Innate Immune ResponseR01AI067497 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, KATHERINE A. · 2006 to 2010
$2.0M
Suppression of the type I IFN gene signature by the long non-coding RNA-Lucat-1R21AI142231 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, KATHERINE A. · 2019 to 2020
$461k
Inc'ing RNA to anti-viral defenseR21AI147208 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, KATHERINE A. · 2019 to 2020
$461k
Regulation of Type I Interferon Gene Expression in the Innate Immune ResponseR56AI067497 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, KATHERINE A. · 2012 to 2012
$415k
NIAID NIH HHS R01 AI067497NIAID NIH HHS R21 AI142231NIAID NIH HHS R21 AI147208NIAID NIH HHS R37 AI067497NIAID NIH HHS R56 AI067497
6 · The paper itself

Abstract

The nuclear long non-coding RNA LUCAT1 has previously been identified as a negative feedback regulator of type I interferon and inflammatory cytokine expression in human myeloid cells. Here, we define the mechanistic basis for the suppression of inflammatory gene expression by LUCAT1. Using comprehensive identification of RNA-binding proteins by mass spectrometry as well as RNA immunoprecipitation, we identified proteins important in processing and alternative splicing of mRNAs as LUCAT1-binding proteins. These included heterogeneous nuclear ribonucleoprotein C, M, and A2B1. Consistent with this finding, cells lacking LUCAT1 have altered splicing of selected immune genes. In particular, upon lipopolysaccharide stimulation, the splicing of the nuclear receptor 4A2 (NR4A2) gene was particularly affected. As a consequence, expression of NR4A2 was reduced and delayed in cells lacking LUCAT1. NR4A2-deficient cells had elevated expression of immune genes. These observations suggest that LUCAT1 is induced to control the splicing and stability of NR4A2, which is in part responsible for the anti-inflammatory effect of LUCAT1. Furthermore, we analyzed a large cohort of patients with inflammatory bowel disease as well as asthma and chronic obstructive pulmonary disease. In these patients, LUCAT1 levels were elevated and in both diseases, positively correlated with disease severity. Collectively, these studies define a key molecular mechanism of LUCAT1-dependent immune regulation through post-transcriptional regulation of mRNAs highlighting its role in the regulation of inflammatory disease.

Indexed as

Nuclear Receptor Subfamily 4, Group A, Member 2RNA, Long NoncodingCell MovementCell ProliferationHumansInflammationReceptors, Cytoplasmic and NuclearRNA SplicingRNA Stabilitylong non-coding RNA LUCAT1, humanNR4A2 protein, humanNuclear Receptor Subfamily 4, Group A, Member 2Receptors, Cytoplasmic and NuclearRNA, Long NoncodinginterferonlncRNAsplicing

Identifiers

PMID36577072
PMCPMC9910463
OpenAlexW4313418721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.